U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Draft Guidance for Industry: Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Draft Guidance for Industry: Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements February 2023

Draft

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2023-D-0451
Issued by:
Guidance Issuing Office
Center for Food Safety and Applied Nutrition

The purpose of this guidance is to provide FDA’s current view on the naming of plant-based foods that are marketed and sold as alternatives for milk (plant-based milk alternatives) in accordance with sections 403(a)(1) and 403(i)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 343(a)(1) and 343(i)(1)). The guidance also includes our recommendations on the use of voluntary nutrient statements. Industry’s use of these voluntary nutrient statements would provide consumers with additional nutrition information to help them understand certain nutritional differences between these products and milk and make informed dietary choices. 

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law.  FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.

Download the Draft Guidance


Related Information


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2023-D-0451.

 
Back to Top